Company: Allakos Inc.
Symbol: ALLK
Description: They are are a clinical stage biotechnology company developing AK002, our wholly owned monoclonal antibody, for the treatment of various eosinophil and mast cell related diseases.
Trade Date: 7/19
Shares: 6 million
Price Range: $15.00-$17.00
Underwriter(s):Goldman Sachs, Jefferies
Co-Manager(s): William Blair
Terms Added: 7-9-18
Business: They are a clinical stage biotechnology company developing AK002, their wholly owned monoclonal antibody, for the treatment of various eosinophil and mast cell related diseases. AK002 demonstrated pharmacodynamic activity in both of their completed Phase 1 trials, and in the single ascending dose Phase 1 trial involving patients with indolent systemic mastocytosis (“ISM”), patients reported improvements in their symptoms. AK002 selectively targets both eosinophils and mast cells, which are types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. As such, AK002 has the potential to treat a large number of severe diseases. They are developing AK002 for the treatment of eosinophilic gastritis (“EG”) and eosinophilic gastroenteritis (“EGE”). In addition, they are conducting studies in ISM, chronic urticaria (“CU”) and severe allergic conjunctivitis (“SAC”) and are evaluating additional indications for future development.
Insider Buying: Certain of theirr principal stockholders, including entities affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of approximately $35.0 million in shares of our common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers in this offering.
Private Placement: New Enterprise Associates 16, L.P., an existing stockholder of ours, has indicated an interest in purchasing approximately $10.0 million in shares of theirr common stock at the initial public offering price in a proposed private placement that would close concurrently with this offering.
Book-Building Status: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance to showcase the value of IPO Boutique’s service.
Indicate with confidence, SUBSCRIBE today.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish